NEW ALZHEIMER'S DISEASE ANIMAL MODEL

Abstract

The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.

Claims

1. A vector comprising a nucleic acid sequence that encodes both an Amyloid Precursor Protein (APP) and Presenilin 1 (PS1).

2. (canceled)

3. The vector according to claim 1 which comprises a nucleic acid sequence that encodes an APPsl (SEQ ID NO: 3) protein and a nucleic acid sequence that encodes the PS1 protein M146L.

4. A method for inducing aspects of Alzheimer's disease in a non-human mammal, said method comprising co-administering to the brain of the non-human mammal a gene encoding Amyloid Precursor Protein (APP) and a gene encoding Presenilin 1 (PS1) protein wherein the gene encoding the APP protein and the gene encoding PS1 protein are present in at least one vector, and wherein only the APP protein and the PS1 protein are co-expressible from the at least one vector; and wherein co-expression of said APP and said PS1 in the brain of the non-human mammal results in the non-human mammal exhibiting behavior suggestive of anxiety and lack of long term memory; and wherein co-expression of said APP and said PS1 in the brain of the non-human mammal leads to production of APP and neurotoxic catabolites of APP from one month after administration and up until at least 12 months after administration without the appearance of classical AD late symptoms.

5. (canceled)

6. The method according to claim 4 wherein the vector is delivered by stereotactic injections or microinjections directly into the brain.

7. (canceled)

8. A non-human mammal having symptoms of Alzheimer's disease wherein the symptoms of Alzheimer's disease are induced by a method comprising administering to the non-human mammal at least one vector containing a nucleic acid sequence that encodes an APP protein or a variant thereof and a nucleic acid sequence that encodes a PS1 protein or a variant thereof, and wherein only the APP protein and the PS1 protein are co-expressible from the at least one vector, wherein co-expression of said APP and said PS1 in the brain of the non-human mammal results in the non-human mammal exhibiting behavior suggestive of anxiety and lack of long term memory; and wherein co-expression of said APP and said PS1 in the brain of the non-human mammal leads to production of APP and neurotoxic catabolites of APP from one month after administration and up until at least 12 months after administration without the appearance of classical AD late symptoms.

9. (canceled)

10. The non-human mammal of claim 8, wherein the non-human mammal is a rodent or a primate.

11. A method of screening a compound for therapeutic use in the treatment of Alzheimer's disease comprising administering to non-human mammal having systems of Alzheimer's disease as set forth in claim 8 a compound to be screened for therapeutic use; measuring accumulation of APP and/or neurotoxic metabolites in the non-human mammal having symptoms of Alzheimer's disease; and selecting the compound as a therapeutic drug if accumulation of APP and/or neurotoxic metabolites is decreased in the non-human mammal having symptoms of Alzheimer's disease compared to a control or to the non-human mammal prior to administration of the compound.

12. The vector according to claim 1, wherein the vector is an AAV9 or an AAV10 vector.

13. The method of claim 4, wherein the non-human mammal is a rodent or a primate.

14. The method of claim 4, wherein the at least one vector is an AAV9 or AAV10 vector.

15. The non-human mammal of claim 8, wherein the at least one vector is an AAV 9 or AAV10 vector.

16. The method of claim 4, wherein the classical AD late symptoms include one or more of deposition of senile plaque, inflammation and atrophy.

17. The method of claim 4, wherein the neurotoxic catabolites of APP include one or more of sAPP, CTF and A42.

18. The method of claim 8, wherein the classical AD late symptoms include one or more of deposition of senile plaque, inflammation and atrophy.

19. The method of claim 8, wherein the neurotoxic catabolites of APP include one or more of sAPP, CTF and A42.

20. The method of claim 4, wherein the gene encoding the APP protein and the gene encoding the PS1 protein are present on a single vector.

21. The non-human mammal of claim 8, wherein the nucleic acid sequence that encodes an APP protein or a variant thereof and the nucleic acid sequence that encodes a PS1 protein or a variant thereof are present on a single vector.

Description

FIGURES

[0091] FIG. 1A-B. Western blot analysis of transgene expression. (A) Representative Western blots of PS1 M146L, human APP (hAPP) and human+murine APP (total APP: tAPP) in hippocampus homogenates transduced by AAV9 or AAV10 vectors carrying the PS1 M146L (PS1*), APPsl (APP) and/or APPsl+PS1 M146L (APP/PS1*) transgenes. (B) A densitometric analysis of the immunoreactivities to the antibodies shown in panel A confirms effective expression of our transgenes.

[0092] FIG. 2. Amyloidogenic processing of APP. APP protein is cleaved by the secretase which leads to the production of soluble fragment sAPP and CTF fragment that remains anchored in the membrane. The CTF is then cleaved by the PS1 (belonging to the secretase complex) allowing production of A42 and A40 peptides.

[0093] FIG. 3A-D. Simultaneous intracerebral injection of AAV10-APPsl and AAV10-PS1 M146L in 8 weeks old C57BL/6J mice induce amyloid cascade one month after injection. APP is metabolized to (A) CTF and then (B) A42 peptide. (C) In contrast to APP and CTF that decreased with PS1 M146L overexpression, A42 production is increased confirming the interest of the simultaneous intracerebral injection of both vectors. (D) In accordance, abnormal phosphorylation on Threonine residue 181 of murine Tau was stimulated by the double injection of AAV coding for APP and PS1 M146L genes. In all cases, AAV10 induced greater production of neurotoxic metabolites.

[0094] FIG. 4A-D: Simultaneous intracerebral injection of AAV10-APPsl and AAV10-PS1 M146L in 8 weeks old C57BL/6J mice induce amyloid cascade at least up to five months. (A) The amyloidogenic pathway of APP involved in AD leads to the production of two metabolites of the neurotoxic APP peptides, A42 and CTF into hippocampus. (B) Hippocampal injection of AAV10 vectors encoding the APPsl and PS1 M146L proteins allowed, within the first month, the induction of a significant production of A42 as well as CTF. This production was stable with time (analyzed up to 5 months). (C-D) The presence of neurotoxic metabolites of APP did not induce astrocytosis as determined by a stable expression of the Glial acidic fibrillatory protein (GFAP) (C) but led to increased levels of phosphorylated endogenous Tau (D) in mice hippocampus between 3 and 5 post-injection.

[0095] FIG. 5A-C: Cognitive deficits following simultaneous intracerebral injection of AAV-APPsl and AAV-PS1 M146L. Openfield: (A) Measurement of anxiety levels by analysis of time spent in the periphery relative to the time spent in the center of the apparatus (P/C ratio). The ratio rises when the anxiety of mice rises too. APPsl/PS1 M146L mice thus appeared hyper-anxious compared to PS1 M146L mice (=0.05). Morris water maze: (B) Both groups, APPsl/PS1 M146L and PS1 M146L mice, had an equivalent learning abilities. This learning was confirmed by the appearance of a spatial bias between learning days 1 and 5. (C) Unlike APPsl/PS1 M146L mice, PS1 M146L mice showed a significant preference for the target quadrant suggesting a long term memory impairment of APPsl/PS1 M146L mice 72 hours after learning session (n=8 mice per group).

[0096] FIG. 6A-C: AAV-APP and AAV-PS1 co-injection leads to AD-like production levels of amyloid derivatives. (A) Human APP quantification (6e10 antibody) of hippocampus samples showing a comparison between AAVs injected animals (5 months old, 3 months post-injection, n=3 per group), human controls and AD cases (n=5 per group) and APP/PS1E9 mice (5 months old, n=3). APP levels were normalized to GAPDH. Data are meanss.e.m. One Way Anova: ***p<0.0001. (B) CTF comparative analysis by ELISA between human controls and AD cases, AAV co-injected animals and APP/PS1E9 mice at 5, 14 and 16 months old (n=5, 5, 4, 4, 3, 8, 8 per group respectively). Data are meanss.e.m. One Way Anova: ***p<0.001. (C) Representation of A40/A42 ratio for the same groups described in panel (B). Data are means s.e.m. One Way Anova: **p<0.01; ***p<0.001.

[0097] FIG. 7A-D: AAV-APP and AAV-PS1 co-injection allows a hyperphosphorylation of the murine Tau protein from 1 month post-injection. (A) P-Tau (AT270, Thr181) comparative analysis by ELISA between AAV10 injected animals (1 month post-injection, n=3-5 mice per group). (B) GSK-3 comparative analysis by ELISA between AAV10 injected animals (n=3-5 mice per group). One Way Anova: *p<0.05. (C) P-Tau (AT270, Thr181) comparative analysis by ELISA showing significant higher levels in the APP/PS1 group at 3 months post-injection (n=3-5 mice per group). One Way Anova: *p<0.05. (D) Evolution of endogenous Tau hyperphosphorylation over time using four independent experiments with 1 or 3 months old mice (n=17-24 mice per group). Two Way Anova: *p<0.05 (Time effect); **p<0.005 (Group effect).

[0098] FIG. 8A-B: AAV-APP and AAV-PS1 co-injection causes a neuronal network failure 3 months post-injection. (A) Western-blot analysis of PSD-95 performed from hippocampus samples showing a comparison between PS1 and APP/PS1 mice at 3 months post-injection (n=4 per group). Data are meanss.e.m and were normalized by GAPDH. t-test, p=0.007. (B) Tonic Glutamatergic Current recorded at a holding potential of +40 mV by whole-cell patch-clamp of CA1 pyramidal neurons.

[0099] FIG. 9A-B: AAV-APP and AAV-PS1 co-injection leads to a reduction of gabaergic synaptic marker Gad65. (A) Western-blot analysis of Gad65 performed from hippocampus samples showing a comparison between PS1 and APP/PS1 mice at 3 months post-injection (n=4 per group). Data are meanss.e.m and were normalized by GAPDH. t-test. (B) Western-blot analysis of Gad65 performed from hippocampus samples showing a comparison between human controls and AD cases (n=5 per group). Data are meanss.e.m and were normalized by GAPDH. t-test.

[0100]

TABLE-US-00007 TABLE 1 Comparative table of some AAV models of AD. Comparative view of some AD models induced by AAV injection. This comparative analysis is based on classical specifications in AD like neurotoxic peptides production and behavioral failures. Peptides production Number Overexpressed Phosphorylated Memory Behavioral AAV models Species of viruses proteins APP A42 A40 -CTF Tau defects defects AAV-APP.SLA (Jaworski et al.) Mouse 1 APPsla Yes ND ND ND Yes ND Yes AAV-BRI-A42 (Lawlor et al.) Rat 1 A42 No Yes No No ND No Yes AAV-BRI-A40 (Lawlor et al.) Rat 1 A40 No No Yes No ND No Yes AAV-BRI-A42/AAV-BRI-A40 Rat 2 A42 & A40 No Yes Yes No ND No Yes (Lawlor et al.) AAV-APPsw (Lawlor et al.) Rat 1 APPsw Yes No Yes ND ND No ND AAV-A42 (Drummond et al.) Mouse 1 A42 No No No No ND ND ND AAV-A40 (Drummond et al.) Mouse 1 A40 No No No No ND ND ND AAV-C100 (Drummond et al.) Mouse 1 -CTF No No No Yes ND ND ND AAV-Tau-P301L (Jaworski et al.) Mouse 1 Tau No No No No Yes ND ND Model of the invention Mouse 2 APPsl & PS1* Yes Yes No Yes Yes Yes Yes

TABLE-US-00008 TABLE 2 Comparative table of some transgenic models of AD. Update of transgenic animal models of AD with a comparison of neurotoxic peptides and cognitive functions onset. Peptides production Phosphorylated Memory Behavioral Overexpressed A42 B-CTF Tau defects defects Gold standard models proteins (in months) (in months) (in months) (in months) (in months) PDAPP (Weiss et al.) APP 8 13 3 Tg2576 (Westerman et al.) APP 6 6 TgAPP23 (Wolf et al.) APP 6 12 3 10 J20 (Palop et al.) APP 2 6 TgCRND8 (Nalbantoglu et al.) APP 6 3 TgCTF104 (Nalbantoglu et al.) -CTF No Yes 8 TgCTF99/B6 (Lee et al.) -CTF No 4 7 13 BRI-A42A (McGowan et al.) A42 3 APPswe/PS1dE9 (Kim et al.) APPsl & PS1 7 Yes No 8 7 5x FAD (Devi et al.) APPsl & PS1 1.5 4 JNPL3 (Lewis et al.) Tau No No 3 V337M tg (Tanemura et al.) Tau No No 11 11 THY-Tau22 (Schindowski et al.) Tau No No 3 6 6 3x Tg (Oddo et al.) APPsl, PS1 & Tau 4 6 Model of the invention APPsl & PS1* 1 1 3 2.5 2.5

EXAMPLE

[0101] Material & Methods

[0102] Tissue Collection

[0103] Test mice were anesthetized with ketamine/xylazine and perfused transcardially with 20 ml PBS. One hemisphere was post-fixed for 24 h in 4% PFA, cryoprotected in 30% of sucrose in PBS and cut into 40 m sections using a freezing microtome for immunohistochemical and histological analyses (data not shown). The other half was frozen immediately on dry ice and used for Western blots and ELISAs.

[0104] ELISAs and Western Blots

[0105] Mice hippocampal tissue was homogenized in a lysis buffer (TBS, NaCl 150 mM, Triton 1%, Phosphatase and Protease inhibitors) and centrifugated 20 at 13000 rpm. Protein levels were normalized by BCA protein assay (Pierce Biotechnology). Extracted A was then measured using the MSD Human A42 Kit. CTF was measured using the IBL Human CTF Kit and the P-Tau using the Innogenetics Phospho-Tau 181P Kit. Aliquots of protein were electrophoretically separated using NuPAGE Bis-Tris Gels (Life Technologies). Electrophoresed proteins were then transferred to nitrocellulose membranes using the iBlot 7-Minute Blotting System, blocked in Tris-buffered saline containing 5% non-fat dry milk and subsequently hybridized with various primary antibodies: APP 6E10 (Sigma), APP Cter (Calbiochem) and Presinilin 1 (Millipore). Densitometry quantification of bands was realised with the Bio1D software.

[0106] Behavioral Analysis

[0107] Open Field:

[0108] Movement in an open field was used to assess whether APP and PS1 injection had an effect on anxiety which may affect memory and learning behaviors. Mice were placed in the center of a square field. The amount of time spent at the periphery along the walls was recorded as measures of anxiety.

[0109] Morris Water Maze:

[0110] The Morris water maze (MWM) task quantifies mice memory abilities (Morris, 1984). This test was used as a measure of spatial learning, the mouse must learn the location of a hidden platform by referring to visual cues placed around the room. The platform location was kept constant throughout training but the starting point varied between trials. MWM consists of five consecutive learning days (3 trials per day). Seventy-two hours after the last trial of the fifth day a probe trial is realized to quantify long-term memory. In both testing phases, distance traveled in the quadrant containing the platform or target quadrant is quantified. An effective memory storage must therefore be accompanied by the establishment of a spatial bias characterized by a distance travelled in the target quadrant over than 25%.

[0111] Results

Example 1: Relevance of the Animal Model

[0112] To evaluate the relevance of our model, we have performed a comparative study between AAV9 and AAV10 vectors encoding the codon-optimized human APP (APPsl, Swedish-London mutations, promoting the cleavage by secretase complex) and/or PS1 M146L (M146L) transgenes in mice (FIG. 1). Stereotactic injections were performed bilaterally in the hippocampus, an early-affected region in AD.

[0113] These results show that the expression of human APPsl by gene transfer leads to lowly increase the total quantity of APP. Co-express with the PS1 M146L, human APP and CTF amount decrease due to APP metabolization by secretase complexes. Moreover, AAV10 virus seems to be better to efficiently produce human APP in mice than AAV9 virus.

[0114] AD is characterized by the amyloidogenic pathway of APP metabolism that results from the cleavage of APP by PS1 (FIG. 2). Animals injected with AAV vector encoding human PS1 M146L protein only (control animal) or with AAV vectors encoding the APPsl and PS1 M146L were sacrificed at 1 month post-injection for histopathological (data not shown), and biochemical and molecular studies (FIG. 3).

[0115] We confirmed by immunohistochemistry our results showed in FIG. 1: AAV10 seems to be better than AAV9 to express APP, in particular in CA2 and Subiculum regions of the hippocampus (data not shown). Co-expression of APPsl and PS1 M146L leads to decreased concentration of CTF as revealed by APP C-ter antibody, or 4G8 antibody staining (data not shown). Expression of PS1 M146L leads to increased metabolism of CT in A42 peptides as explained in FIG. 2.

Example 2: Production of Metabolites in the Animal Model

[0116] APP is cleaved into different metabolites like C-terminal fragment of APP (CTF) and A42 peptide with characterized neurotoxic properties. We showed that expression of PS1 M146L leads to increased metabolism of CTF in A42 peptides. Indeed decreased concentration of CTF is observed in the hippocampus of mice co-injected with AAV10-APPsl and AAV10-PS1 M146L vectors (FIG. 3).

[0117] The amount of CTF showed respectively a 56- and 25-fold increase for APPsl and APPsl/PS1 M146L mice compared to PS1 M146L control mice one month after injection (FIG. 3A). Overexpression of human APPsl thus significantly promotes the production of CTF. CTF concentration is decreased in APPsl/PS1 M146L mice compared to APPsl mice, demonstrating increased metabolism of CTF with overexpression of PS1 M146L. CTF was also detected in cortical structures in the absence of cortical production sites which argues for diffusion of CTF produced into the hippocampus towards the cortical structures (data not shown). A42 (the main neurotoxic peptide in AD) production is, on the other side, strongly increased in APPsl/PS1 M146L mice.

[0118] A longitudinal study was performed to analyze the kinetics of neurotoxic peptides production in mouse brain (FIG. 4). A statistically significant (43 fold) increase of A42 peptides production was observed in mice injected with both AAV10-APPsl and AAV10-PS1 M146L vectors in the hippocampus (p=0.002). CTF production also showed a significant 15-fold increase (p=0.0001). In addition, evidence of murine Tau hyperphosphorylation (Threonine residue 181) appeared between 3 and 5 months after injection (p=0.03).

Example 3: Behavioral Analysis of the Animal Model

[0119] At 2.5 months post-injection, a behavioral study was performed in injected animals (FIG. 5) for a period of 2.5-3 months. The Openfield test was used to evaluate spontaneous locomotion of mice and behavior response to a new environment. The ratio between time spent in the periphery (noted P, area less anxiogenic) and in the center (noted C) of the open field was significantly increased in APPsl/PS1 M146L mice compared to PS1 M146L mice (p<0.05), suggesting an increased level of anxiety in APPsl/PS1 M146L mice.

[0120] During the learning phase of the Morris water maze test, no learning defect was observed in APPsl/PS1 M146L compared to PS1 M146L control mice The two groups had therefore a normal learning profile. During the restitution phase of acquired information (72 hours retention time), a failure to return to platform quadrant previously acquired was observed in APPsl/PS1 M146L mice. The distance traveled by the mouse PS1 M146L in the target quadrant (TQ) was significantly greater than in other quadrants (p=0.01) confirming the presence of a spatial bias. The presence of this spatial bias was not observed for APPsl/PS1 M146L mice (p=ns). So APPsl/PS1 M146L mice traveled less distance in the quadrant previously containing the platform. These results confirm a lack of long-term memory in these mice compared to control mouse PS1 M146L (p=0.02).

[0121] In conclusion, AAV-APPsl and AAV-PS1 M146L injection in wild type mouse leads to rapid (1 month) and stable (evaluated up to 5 months) increased production of amyloid peptides, hyperphosphorylation of endogenous Tau protein and cognitive deficits in mice, parameters which are characteristics of Alzheimer's disease.

[0122] Such models could be useful to analyze deleterious mechanisms induced by amyloid pathway, as well as to evaluate biomarkers or screen therapeutic approaches.

Example 4: Advantages of Animal Model of the Invention from Other Models

[0123] The generation of AD animal models aims to reproduce symptoms, injuries or causes similar to those observed in the human disease. Many strains of transgenic mice are successful to reproduce these lesions: extracellular deposits of AB peptide and intracellular accumulation of Tau protein. However the existing models are imperfect. To identify new therapeutic targets and the effectiveness of treatments in AD, various pharmaceutical companies have developed their own mouse models. Some companies also developed/used different models for provision of services as Contract Research Organizations (CROs).

[0124] These models have specific drawbacks: [0125] Transgenic models have an important expression of transgenes from the embryonic stages of development which will ultimately lead to the establishment of adaptive mechanisms. In addition, the cost of production is very high. They often imperfectly reproduce the AD phenotype and are difficult to transpose to larger species. Obtain models of AD in large species (rats and primates in particular) would be crucial to develop biomarkers and validate therapeutic approaches in a context as close as possible to the human pathophysiology. [0126] Models by intracerebral injection of amyloid peptides, truncated or not, are very easy to develop, relatively inexpensive and do not induce adaptive mechanisms. However, they suffer from several drawbacks: in addition to providing a partial model of AD, they do not have all the neurotoxic products generated in AD and in particular CTF, products described as highly neurotoxic even at low doses. The administered concentrations of A42 or 25-35 are much higher than those observed in human pathological conditions. These models are therefore particularly suitable for measuring the neuroprotective ability of drugs but have a reduced interest to characterize compounds that modulate the pathological APP metabolism or intracellular changes resulting from the production of neurotoxic metabolites derived from APP.

[0127] In comparison with current transgenic models, the present AAV-APPsl/AAV-PS1 M146L model offers many advantages (see table 2): [0128] No establishment of breeding colony, but induction of on-demand model, on standard commercial animals with an expression of toxic metabolites of APP at one month after injection: saving time (at least one year for the establishment of sufficient colony to produce experimental batches) and financial gain (no need to decontaminate strains before implantation nor to keep the breeding continuously). [0129] Ability to induce amyloid pathology in specific transgenic mouse lines. It could be useful to determine the involvement of new therapeutic targets (for example to understand a hypothetic involvement of the kinase DIRK1A in AD we could induce the amyloid pathology by these constructions in a model of mice over-expressing DIRK1A protein). [0130] The use of a model by gene transfer overcomes two major drawbacks of transgenic models: 1) continuous transgenes expression from in utero, 2) limitation of the transgenesis to mice. The transfer of this technology in other species (particularly rats & non-human primates) will allow imaging studies, search for biomarkers in cerebrospinal or blood fluids and more advanced cognitive tests.

[0131] As compared to models by injection, our model has many advantages (see table 1): [0132] Production of all neurotoxic metabolites derived from APP (A42 and CTF) [0133] Continuous production of all neurotoxic APP derivatives [0134] Pathophysiologic production level

[0135] Thus, a mouse model (and/or rat) of Alzheimer's disease by gene transfer would be a powerful tool that would combine the advantages of transgenic animals (complete and stable modeling of the amyloid cascade) without the inconvenience of adaptive mechanisms, and with reduced production costs. Such model could be a major alternative for companies like CROs.

Example 5: Gene Transfer Leads to APP and Cleavage Products Levels Close to Humans

[0136] In order to confirm the relevance of this strategy compared to human physiopathology, we performed a comparative study between hippocampus homogenates from 3 months old APP/PS1 mice, human samples (age matched non dementia controls & AD Braak 6/Thal 5 patients; n=5/group) and 5 months old APP/PS1E9 commonly used as gold standard.

[0137] An APP decrease was observed in both pathologic groups i.e. AAV-APP/PS1 and AD Braak VI Thal V patients (FIG. 6A) in comparison to their respective controls. In contrast to APP/PS1 mice, a significant higher amount of human APP (n=3-5 samples per group, ***p<0.0001) was measured in APP/PS1E9 transgenic mice (FIG. 6A) which furthermore increase with age (data not shown). We further evaluated the total APP amount (murine+human forms). Strikingly, there was no significant overproduction of total APP in contrast to APP/PS1E9 mice (data not shown). No APP accumulation over time was measured during at least 12 months post-injection. We then evaluated catabolites derived from the amyloidogenic pathway in the hippocampus. First of all, CTF levels were similar between APP/PS1 mice and AD patients. Significant higher levels were measured in APP/PS1E9 mice confirming age-dependent APP and CTF accumulation in these animals (FIG. 6B; n=3-8 samples per group, ***p<0.0001). Thus, ELISA revealed APP/PS1 A42 amounts comprised between controls and AD patients. Higher levels were observed in transgenic mice. In addition, no significant difference appeared between A40 levels between human samples and AAV mice unlike with transgenic samples. We finally calculated the A40/A42 ratio and similar values were obtained between AD patients and APP/PS1 group. Interestingly it appeared that 16 months old is not sufficient to obtain the same ratio in APP/PS1E9 mice (FIG. 6C). Altogether, our data strongly suggest that amyloid processing due to AAV injection is closer humans that transgenic APP/PS1dE9 mice.

Example 6: APP/PS1 Co-Injection Triggers a Hyperphosphorylation of the Endogenous Tau Protein

[0138] Given the evidence that human APP is processed following the amyloidogenic pathway we examined the potential impact on the hyperphosphorylation of the murine Tau. We detected an increase in the APP/PS1 group (n=4) compared to the APP (n=4) and PS1 (n=4) groups (FIG. 7A). We also measured a higher amount of GSK-3, key kinase implicated in the Tau phosphorylation (FIG. 7B). ELISA assay realized on 3 months old APP/PS1 mice showed thereby a significant hyperphosphorylation of Tau (FIG. 7C; n=3-4 mice per group, *p<0.05). To ensure that there is indeed a trend concerning the phosphorylation state of Tau, we performed a comparative analysis between the APP and APP/PS1 group normalized on PS1 group (FIG. 7D). Data cumulated from four different experiments with 1 or 3 months old mice were used (n=17-24 mice per group) and showed a significant effect of group (**p<0.005) and time (*p<0.05) suggesting an exacerbation of tau phosphorylation over time.

Example 7: APP/PS1 Mice Present a Failure of the Neuronal Network

[0139] It is well known that synaptic dysfunctions appear as an early event in AD (Scheff et al., 2007). Some synaptic markers like PSD-95 have been showed as reduced in AD patients (Proctor et al., 2010). We evaluated PSD-95 levels in the hippocampus of our model at 3 months post-injection. A significant decrease appeared in the APP/PS1 group compared to PS1 group (FIG. 8A; n=4 per group, p=0.007). Whole-cell patch-clamp recording of CA1 pyramidal cells was performed and Tonic Glutamatergic Current was recorded. Significant increase appeared in the APP/PS1 group meaning that Glutamate activate preferentially extrasynaptic NMDARs in this group (FIG. 8B; n=11-19 per group).

Example 8: APP/PS1 Mice Present an Altered GABA Pathway

[0140] Increasing evidences appeared these past few years about a decreased GABAergic signaling in AD patients (Gang et al., 2009; Xue et al., 2014; Tiwari et al., 2012). Using a 11.7 Tesla MRI, Magnetic Resonance Spectroscopy analysis was performed on PS1 and APP/PS1 mice at 3 months post-injection (n=6 per group). The region of interest was selected in both hippocampus of each mouse brain (data not shown). Results for the APP/PS1 were normalized to the PS1 values. APP/PS1 mice have significantly lower concentrations of Glutamine (Gln; p=0.017), GABA (p=0.018) and NAA (p=0.04) than PS1 mice indicating a decreased neuronal health and particularly a decreased GABA signaling pathway. No differences were obtained between both groups in the levels of Glu, tNAA, Ins and tChol (data not shown). Glutamine is the precursor of Glutamate which is itself the precursor of the GABA neurotransmitter. To explain why we observed a decrease of Glutamine and GABA but not of Glutamate, we looked for the Gad65 expression. Gad65 is an enzyme which catalyzes the decarboxylation of Glutamate to GABA for neurotransmission. It appeared decreased in the APP/PS1 mice at 3 months after injection compared to PS1 mice (FIG. 9A; n=4 mice per groups, p=0.03). Interestingly, a decrease of Gad65 was also shown in human patients compared to control patients (FIG. 9B; n=5 patients per groups, p=0.1).

Example 9: Injection of the CAG-APP-T2A-PS1 Construct

[0141] We generate an AAV vector coding for a fusion protein containing APP and PS1 protein spaced by a self-cleaving peptide (T2A peptide). Mice injected with CAG-APP-T2A-PS1 construction present production of neurotoxic metabolites of APP (CTF, A38/40/42) close to human amounts. Hyperphosphorylation of murine TAU protein is also observable. These cerebral changes lead to behavioral defects in Morris water maze.

CONCLUSION

[0142] The inventors describe here the development of an alternative AAV-based mouse model with two major objectives: create a relevant model closer to human physiopathology and mimic the early stages of AD. This model was obtained by co-injection, in the hippocampus of wild-type mice, of two AAV vectors coding the human Amyloid Protein Precursor (APPsl) and the human Presinilin 1 (PS1M146L). Our strategy allows a stable expression of transgenes without significant APP overexpression. This leads to APP production and its neurotoxic catabolites such as sAPP, CTF and A42 as soon as one month post-injection and stable during at least 12 months without classical late symptoms appearance such as senile plaque, inflammation or atrophy. Otherwise, they measured very close amounts of APP, CTF and A peptides compared to human homogenates and unlike what we can find in APP/PS1E9 mice. Interestingly, only co-injection triggered hyperphosphorylation of the murine Tau protein resulting from an increase of GSK-3 levels. Finally, significant behavior impairments appeared from 3 months post-injection in association with an alteration of synaptic functions especially a decrease of PSD-95 associated with synaptic defects such as extrasynaptic NMDAR activity and an alteration in the GABAergic pathway.

REFERENCES

[0143] Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure. [0144] Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823, doi:10.1126/science.1171242 (2009). [0145] Deglon, N. & Hantraye, P. Viral vectors as tools to model and treat neurodegenerative disorders. The journal of gene medicine 7, 530-539, doi:10.1002/jgm.707 (2005). [0146] Devi, L. & Ohno, M. Phospho-elF2alpha level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PloS one 5, e12974. doi:10.1371/journal.pone.0012974 (2010). [0147] Drummond, E. S. et al. Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum. PloS one 8, e59166, doi:10.1371/journal.pone.0059166 (2013). [0148] Jaworski, T. et al. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PloS one 4, e7280, doi:10.1371/journal.pone.0007280 (2009). [0149] Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489, doi:10.1126/science.1079469 (2003). [0150] Kim, T. K. et al. Analysis of differential plaque depositions in the brains of Tg2576 and Tg-APPswe/PS1dE9 transgenic mouse models of Alzheimer's disease. Experimental & molecular medicine 44, 492-502, doi:10.3858/emm.2012.44.8.056 (2012). [0151] Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. The Journal of neuroscience: the official journal of the Society for Neuroscience 22, 2780-2791, doi:20026246 (2002). [0152] Lawlor, P. A. et al. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Molecular neurodegeneration 2, 11, doi:10.1186/1750-1326-2-11 (2007). [0153] Lee, J. E. & Han, P. L. An update of animal models of Alzheimer's disease with a reevaluation of plaque depositions. Experimental neurobiology 22, 84-95, doi:10.5607/en.2013.22.2.84 (2013). [0154] Lee, K. W. et al. Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein. Neurobiology of disease 22, 10-24, doi:10.1016/j.nbd.2005.09.011 (2006). [0155] Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491, doi:10.1126/science.1058189 (2001). [0156] Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N. & Aebischer, P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 99, 10813-10818, doi:10.1073/pnas.152339799 (2002). [0157] Nalbantoglu, J. et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387, 500-505, doi:10.1038/387500a0 (1997). [0158] McGowan, E. et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199, doi:10.1016/j.neuron.2005.06.030 (2005). [0159] Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P. & LaFerla, F. M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiology of aging 24, 1063-1070 (2003). [0160] Palop, J. J. et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proceedings of the National Academy of Sciences of the United States of America 100, 9572-9577, doi:10.1073/pnas.1133381100 (2003). [0161] Schindowski, K. et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. The American journal of pathology 169, 599-616, doi:10.2353/ajpath.2006.060002 (2006). [0162] Selkoe, D. J. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 98, 11039-11041, doi:10.1073/pnas.211352598 (2001). [0163] Tanemura, K. et al. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. The Journal of neuroscience: the official journal of the Society for Neuroscience 22, 133-141 (2002). [0164] Weiss, C. et al. Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice. Neurobiology of disease 11, 425-433 (2002). [0165] Westerman, M. A. et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 22, 1858-1867 (2002). [0166] Wolf, S. A. et al. Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biological psychiatry 60, 1314-1323, doi:10.1016/j.biopsych.2006.04.004 (2006).